Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Uncategorized Page 3

Uncategorized

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

William Leonard Pickard interviews Bryan Hubbard about the new policy frontier of Ibogaine

Psychedelic legend “the Acid King” William Leonard Pickard Announced as Keynote Speaker at the 2025 North Florida Entheogenic Conference

Hello world!

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

atai Life Sciences to Participate in the Cowen 43rd Annual Health...

Expanding ketamine’s horizons for rare neurological disorders

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from...

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101...

atai Life Sciences Announces Results from the Kures Therapeutics Phase 1...

atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for...

The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort...

atai Life Sciences Reports Third Quarter 2022 Financial Results and Business...

atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil...

atai Life Sciences Reports Third Quarter 2022 Financial Results and Business...

Load more

EDITOR PICKS

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©